12:00 AM EDT, 08/31/2026 (MT Newswires) -- Zambon received marketing authorization from the European Commission for Hopledo to treat moderate to severe motor fluctuations in adults with Parkinson's disease. The pharmaceutical company said Aug. 28 it supported its application for the oral, modified-release formulation of levodopa/carbidopa with data from the phase 3 Rise-PD clinical trial. The approval follows the positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use. Commercial rollout of Hopledo in the European Union is expected to begin in October.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.